Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials

IF 3.9 2区医学 Q1 PSYCHIATRY

Drug and alcohol dependence Pub Date : 2024-09-07 DOI:10.1016/j.drugalcdep.2024.112424

{"title":"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials","authors":"","doi":"10.1016/j.drugalcdep.2024.112424","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Increasing evidence suggests that GLP-1 receptor agonists (GLP-1RA) have a potential use in addiction treatment. Few studies have assessed the impact of GLP-1RA on substance use disorder (SUD), particularly in humans. The study aimed to do systematic review of clinical trials to assess GLP-1RA's effect on reducing SUD in patients.</p></div><div><h3>Methods</h3><p>The scientific literature was reviewed using the MEDLINE, Scopus and Cochrane Library databases, following PRISMA guidelines. Studies including patients with a diagnosis of SU who were treated with GLP-1RA were selected. The primary outcome was GLP-1RA's therapeutic effect on SUD, and the secondary outcomes were therapeutic effects of GLP-1RA on weight, BMI and HbA1c.</p></div><div><h3>Results</h3><p>1218 studies were retrieved, resulting in 507 papers after title and abstract screening. Following full-text review, only 5 articles met inclusion criteria. We incorporated a total of 630 participants utilizing Exenatide (n=3) and Dulaglutide (n=2) as GLP-1RAs. Therapeutic effect of GLP-1RA on SUD was assessed in 5 studies, with 3 demonstrating a significant decrease in SUD (alcohol and nicotine). GLP-1RA's impact on body weight, BMI, and HbA1c, was reported in 3 studies. These revealed a notable reduction in these parameters among the GLP-1RA treated group.</p></div><div><h3>Conclusion</h3><p>This review will give an overview of current new findings in human studies; we suggest that the effects of GLP-1RA in SUD is a possible new option of therapy in addiction medicine.</p></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0376871624013498/pdfft?md5=dd700358e8821ab7d884c2fdd369f53a&pid=1-s2.0-S0376871624013498-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol dependence","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0376871624013498","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Increasing evidence suggests that GLP-1 receptor agonists (GLP-1RA) have a potential use in addiction treatment. Few studies have assessed the impact of GLP-1RA on substance use disorder (SUD), particularly in humans. The study aimed to do systematic review of clinical trials to assess GLP-1RA's effect on reducing SUD in patients.

Methods

The scientific literature was reviewed using the MEDLINE, Scopus and Cochrane Library databases, following PRISMA guidelines. Studies including patients with a diagnosis of SU who were treated with GLP-1RA were selected. The primary outcome was GLP-1RA's therapeutic effect on SUD, and the secondary outcomes were therapeutic effects of GLP-1RA on weight, BMI and HbA1c.

Results

1218 studies were retrieved, resulting in 507 papers after title and abstract screening. Following full-text review, only 5 articles met inclusion criteria. We incorporated a total of 630 participants utilizing Exenatide (n=3) and Dulaglutide (n=2) as GLP-1RAs. Therapeutic effect of GLP-1RA on SUD was assessed in 5 studies, with 3 demonstrating a significant decrease in SUD (alcohol and nicotine). GLP-1RA's impact on body weight, BMI, and HbA1c, was reported in 3 studies. These revealed a notable reduction in these parameters among the GLP-1RA treated group.

Conclusion

This review will give an overview of current new findings in human studies; we suggest that the effects of GLP-1RA in SUD is a possible new option of therapy in addiction medicine.

查看原文本刊更多论文

胰高血糖素样肽-1（GLP-1）受体激动剂在药物使用障碍中的潜在作用：随机试验的系统回顾

背景越来越多的证据表明，GLP-1 受体激动剂 (GLP-1RA) 有可能用于成瘾治疗。很少有研究评估了GLP-1RA对药物使用障碍（SUD）的影响，尤其是对人类的影响。本研究旨在对临床试验进行系统性回顾，以评估 GLP-1RA 对减少患者 SUD 的影响。方法按照 PRISMA 指南，使用 MEDLINE、Scopus 和 Cochrane Library 数据库对科学文献进行了回顾。筛选出包括诊断为 SU 并接受 GLP-1RA 治疗的患者在内的研究。主要研究结果为 GLP-1RA 对 SUD 的治疗效果，次要研究结果为 GLP-1RA 对体重、BMI 和 HbA1c 的治疗效果。全文审阅后，只有 5 篇文章符合纳入标准。我们共纳入了 630 名使用艾塞那肽（n=3）和度拉鲁肽（n=2）作为 GLP-1RAs 的参与者。5 项研究评估了 GLP-1RA 对 SUD 的治疗效果，其中 3 项研究显示 SUD（酒精和尼古丁）显著减少。有 3 项研究报告了 GLP-1RA 对体重、体重指数和 HbA1c 的影响。结论本综述将概述目前人类研究的新发现；我们认为，GLP-1RA 对 SUD 的影响可能是成瘾医学治疗的一种新选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug and alcohol dependence 医学-精神病学

CiteScore

7.40

自引率

7.10%

发文量

409

审稿时长

41 days

期刊介绍： Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.